Doug Ingram, Sarepta credit BCG
Sarepta shares slammed on report gene therapy Duchenne MD patient was hospitalized, but the company says it is 'erroneous'
Sarepta has some explaining to do.
The biotech’s shares $SRPT nose dived 13% on Thursday after a report surfaced that one of the children in its gene therapy study was hospitalized with rhabdomyolysis in February, which hit the FDA’s adverse event roster. Its shares then plunged 13% before trading was halted.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.